Table 5.

Multivariable model of FVC decline after initiation of antifibrotic therapy in patients with IPF.

		Beta	95%CI	p-value
Time		−0.18	−0.26 to −0.10	<0.001
Age group 75+ years		0.41	−0.98 to 1.81	0.563
Time × Age group 75+ years		−0.05	−0.20 to 0.09	0.478
Female		−0.37	−1.69 to 0.95	0.581
Death during Follow-up		−1.90	−2.93 to −0.86	<0.001
FVC at treatment start		0.94	0.91–0.97	<0.001
6MWD		0.00	0.00–0.01	0.041
Physician's global assessment of clinical course of IPF
	Slow progression	−2.83	−4.11 to −1.54	<0.001
	Rapid progression	−3.23	−5.69 to −0.78	0.010
Number of comorbidities		0.23	0.00–0.46	0.046

FVC, forced vital capacity; 6MWD, 6 minutes walking distance; IPF, idiopathic pulmonary fibrosis.